long term effects of glp 1 agonists GI Adverse Glucagon-Like Peptide-1 Receptor How GLP-1 Medications Boost Weight
Description
Recent data from Eli Lilly's tirzepatide, may present a serious challenge to Novo Nordisks dominant position in the anti-obesity space
17 in the journal Nature Medicine
This will likely require FDA approval of suzetrigine / VX-548 (potentially by Q1 2025) before an ethical study design is possible, to ensure long term access to suzetrigine for successfully transitioned patients
In a retrospective cohort study of patients with type 2 diabetes, coadministration with serotonergic antidepressants (eg, citalopram/escitalopram) was associated with attenuation of the weight loss effects of GLP-1 agonists
Wyne KL, Litwin SE, Cusi K, Guyton JR
Amylin acts on amylin receptors in the brainstem to reduce food intake [83] and improves glucose metabolism by delaying gastric emptying and inhibiting glucagon secretion [84, 85]
